ACCURAY INC (ARAY) SEC Filings

Accuray Incorporated (ARAY) is registering up to 6,834,308 shares of common stock for resale by existing lenders that hold warrants issued under its senior secured Financing Agreement. The shares consist of 2,990,010 underlying Super Premium Warrants, 2,135,721 underlying Premium Warrants and 1,708,577 underlying Penny Warrants tied to a $18.25 million delayed draw term loan funded on May 19, 2026.

Accuray will not receive proceeds from any resale of these shares, but may receive cash if holders exercise the warrants for cash, which it intends to use for general corporate purposes. The common stock trades on Nasdaq Capital Markets under “ARAY,” and last traded at $0.24 per share on September 10, 2026.

Accuray Incorporated (ARAY) has filed Amendment No. 2 to a Form S-3 shelf registration to cover the resale, from time to time, of up to 6,834,308 shares of common stock by certain lending investors. These shares are issuable upon exercise of Super Premium, Premium and Penny Warrants issued in connection with Accuray’s senior secured financing arrangements, including an $18.25 million delayed draw term loan funded on May 19, 2026. Accuray is not offering any shares itself and will not receive proceeds from stockholder resales, but may receive cash if the warrants are exercised for cash, which it currently plans to use for general corporate purposes.

ACCURAY INC (symbol: ARAY) is the issuer of record for a Form SCHEDULE 13D/A filing submitted to the SEC.

ACCURAY INC (ARAY) reported that TCW Group, Inc., a ten percent owner, indirectly acquired new warrants to purchase a total of 8,585,857 shares of Accuray common stock on July 29, 2026. These consist of warrants for 7,987,743 shares and 598,114 shares, each with a $0.01 exercise price and expiring July 29, 2033.

The warrants were issued by Accuray to TCW-affiliated holders under a Securities Purchase Agreement and a Limited Waiver and Amendment to a Financing Agreement. The filing states that, after this issuance, TCW holds warrants to purchase 27,527,916 Accuray common shares and disclaims beneficial ownership beyond its pecuniary interest. No Rule 10b5-1 trading plan is reported.

Accuray Inc (ARAY) provides radiation therapy systems and software, centered on its CyberKnife robotic platform and a differentiated helical portfolio (Accuray Stellar, Radixact, Accuray Helix and Tomo C). These systems support SRS, SBRT, IMRT, IGRT and adaptive radiotherapy, aiming for precise dose delivery while managing exposure to healthy tissue.

The company also offers treatment planning (Accuray Precision), data management (iDMS), motion tracking (Synchrony), advanced imaging (ClearRT), and workflow/QA tools, plus installation, training and services to build recurring revenue. Strategy focuses on clinical adoption, international expansion, joint ventures (including a China JV for Tomo C), and AI-enabled service tools while improving cost efficiency and supply chain resilience.

Accuray operates under extensive U.S. and international medical device and healthcare regulations, with all current products cleared as Class II devices in the U.S. It reports holding hundreds of patents supporting its technology position and emphasizes ongoing R&D collaborations and talent development to sustain innovation.

ACCURAY INC (symbol: ARAY) is the issuer of record for a Form DEF 14A filing submitted to the SEC.

Accuray Incorporated (ARAY) has filed an amended Form S-3 registration statement to permit the resale, from time to time, of up to 6,834,308 shares of common stock by certain existing lenders as selling stockholders. These shares are issuable upon exercise of previously issued Super Premium, Premium and Penny Warrants granted in connection with Accuray’s senior secured Financing Agreement, including an $18.25 million delayed draw term loan facility funded on May 19, 2026.

Accuray is not issuing or selling any new shares in this registration and will not receive proceeds from selling stockholder resales, though it would receive cash if holders exercise the warrants for cash. As of May 31, 2026, 118,963,696 shares of common stock were outstanding. The warrants have exercise prices of $1.50, $1.25 and $0.01 per share and include price-based anti-dilution protection. Accuray’s stock is listed on the Nasdaq Capital Market under the symbol ARAY, having transferred from the Nasdaq Global Select Market effective August 6, 2026; the last reported price on August 20, 2026 was $0.29 per share.

Accuray Incorporated (ARAY) reported fourth-quarter and fiscal 2026 results showing weaker top-line demand but notable cost and margin actions. For the June 30, 2026 quarter, net revenue was $100.9 million, a 21% decrease from $127.5 million a year earlier, driven by a 42% decline in product revenue to $40.8 million, partially offset by 6% growth in service revenue to $60.1 million. Quarterly gross profit was $35.1 million and gross margin improved to 34.8% from 30.6%, while operating expenses fell 15% to $29.6 million, including $0.7 million of restructuring charges. Adjusted EBITDA rose to $12.9 million from $9.4 million, but the quarter showed a net loss of $1.9 million.

For fiscal 2026, net revenue was $401.9 million, a 12% decrease from $458.5 million, with product revenue down 27% and service revenue up 4%. Full-year gross profit declined to $111.5 million and gross margin to 27.7%, while operating expenses were $137.9 million, including $16.2 million of restructuring; excluding these, operating expenses would have decreased 13% versus the prior year. Accuray recorded a GAAP net loss of $49.2 million ($0.40 per share) and Adjusted EBITDA of $10.6 million. Gross product orders fell to $191.9 million and order backlog to $312.5 million, about 27% lower than a year earlier. Cash, cash equivalents, and short-term restricted cash were $41.2 million at June 30, 2026.